E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 79

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2018

Summary

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation.

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 24 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 7 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Report covers products from therapy areas Oncology and Ophthalmology which include indications Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Leukemias, Osteosarcoma, Refractory Multiple Myeloma, Soft Tissue Sarcoma, Adenoid Cystic Carcinoma (ACC), Blood Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Dedifferentiated Liposarcoma, Essential Thrombocythemia, Follicular Lymphoma, Liposarcoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Uveal Melanoma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Proliferative Vitreoretinopathy (PVR), Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma and Well Differentiated Liposarcoma.

The latest report E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2018, outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)

- The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects

- The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development
Aileron Therapeutics Inc
Amgen Inc
Ascentage Pharma Group Corp Ltd
Boehringer Ingelheim GmbH
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Novartis AG
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles
ALRN-6924 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-7209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APG-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-0252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGM-097 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-50 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-3032 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-5272 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HDM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISA-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMRi-64 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-8994 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit E3 Ubiquitin-Protein Ligase Mdm2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mdm2 and MdmX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit p53-hdm2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit MDMX and MDM2 for Solid and Liquid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development Milestones
Featured News & Press Releases
May 22, 2018: Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute
May 15, 2018: Aileron Therapeutics Announces Changes to Management
Apr 11, 2018: Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia
Mar 28, 2018: Aileron Therapeutics Announces Expansion of Scientific Advisory Board
Mar 19, 2018: Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
Dec 11, 2017: Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent DS-5272 at ASH
Nov 01, 2017: Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
Aug 24, 2017: Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
Jun 03, 2017: Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
May 18, 2017: Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53
Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology
Nov 30, 2016: Daiichi Sankyo Highlights Clinical Data on DS-3032 at the 58th Annual Meeting of the American Society of Hematology
Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53
Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aileron Therapeutics Inc, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
  • Global Compounding Pharmacy Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 17-Aug-2018        Price: US 3480 Onwards        Pages: 129
    The traditional role of compounding pharmacies is to make drugs prescribed by doctors for specific patients with needs that can't be met by commercially available drugs. For example: A young child may need a small, liquid dose of a drug made only in adult-dosage tablets. A person may be allergic to one of the ingredients in the commercial version of a drug. A compounding pharmacy would make the proper dosage and form of the drug without any offending ingredients. Comp......
  • Global Human Prothrombin Complex Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Aug-2018        Price: US 3480 Onwards        Pages: 134
    Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available. Scope of the Report: This report focuses on the Human Prothrombin Complex in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Human Prothrombin Complex Market 2018, Forecast to 2023
    Published: 17-Aug-2018        Price: US 4880 Onwards        Pages: 137
    Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available. Scope of the Report: This report focuses on the Human Prothrombin Complex in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes ......
  • Global Medical Rubber Stopper Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Aug-2018        Price: US 3480 Onwards        Pages: 145
    Medical Rubber Stopper is widely used for the pharmaceutical application which made from butyl rubber and are available in various sizes and styles depending on applications. Scope of the Report: This report focuses on the Medical Rubber Stopper in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The classification of Me......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Medical Rubber Stopper Market 2018, Forecast to 2023
    Published: 17-Aug-2018        Price: US 4880 Onwards        Pages: 145
    Medical Rubber Stopper is widely used for the pharmaceutical application which made from butyl rubber and are available in various sizes and styles depending on applications. Scope of the Report: This report focuses on the Medical Rubber Stopper in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The classification of Me......
  • Global Internal Nasal Dilators Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Aug-2018        Price: US 3480 Onwards        Pages: 128
    Internal Nasal Dilators are small devices that are made from plastic, or rubber. They fit directly into the nostril and remain in place all night to aid your breathing. The dilators are easy to insert and do not cause any undue discomfort when you have them inserted. Scope of the Report: This report focuses on the Internal Nasal Dilators in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Internal Nasal Dilators Market 2018, Forecast to 2023
    Published: 17-Aug-2018        Price: US 4880 Onwards        Pages: 128
    Internal Nasal Dilators are small devices that are made from plastic, or rubber. They fit directly into the nostril and remain in place all night to aid your breathing. The dilators are easy to insert and do not cause any undue discomfort when you have them inserted. Scope of the Report: This report focuses on the Internal Nasal Dilators in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the......
  • Global Self-Monitoring Blood Glucose (SMBG) Devices Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Aug-2018        Price: US 3480 Onwards        Pages: 129
    Self-monitoring of blood glucose (SMBG) is an important component of modern therapy for diabetes mellitus. SMBG has been recommended for people with diabetes and their health care professionals in order to achieve a specific level of glycemic control and to prevent hypoglycemia. The goal of SMBG is to collect detailed information about blood glucose levels at many time points to enable maintenance of a more constant glucose level by more precise regimens. It can be used to aid in the adjustment ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Self-Monitoring Blood Glucose (SMBG) Devices Market 2018, Forecast to 2023
    Published: 17-Aug-2018        Price: US 4880 Onwards        Pages: 131
    Self-monitoring of blood glucose (SMBG) is an important component of modern therapy for diabetes mellitus. SMBG has been recommended for people with diabetes and their health care professionals in order to achieve a specific level of glycemic control and to prevent hypoglycemia. The goal of SMBG is to collect detailed information about blood glucose levels at many time points to enable maintenance of a more constant glucose level by more precise regimens. It can be used to aid in the adjustment ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs